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ABSTRACT 
Patients with HIV present with a higher prevalence of QT prolongation, of which molecular 
bases are still not clear. Among HIV proteins, Tat serves as a transactivator that stimulates 
viral genes expression and is required for efficient HIV replication. Tat is actively secreted 
into the blood by infected T-cells and affects organs such as the heart. Tat has been shown to 
alter cardiac repolarization in animal models but how this is mediated and whether this is also 
the case in human cells is unknown. In the present study, we show that Tat transfection in 
heterologous expression systems led to a decrease in hERG (underlying cardiac IKr) and 
human KCNE1-KCNQ1 (underlying cardiac IKs) currents and to an acceleration of their 
deactivation. This is consistent with a decrease in available phosphatidylinositol-(4,5)-
bisphosphate (PIP2). A mutant Tat, unable to bind PIP2, did not reproduce the observed 
effects. In addition, WT-Tat had no effect on a mutant KCNQ1 which is PIP2-insensitive, 
further confirming the hypothesis. Twenty four-hour incubation of human induced pluripotent 
stem cells-derived cardiomyocytes with Wild-type Tat reduced IKr and accelerated its 
deactivation. Concordantly, this Tat incubation led to a prolongation of the action potential 
(AP) duration. Events of AP alternans were also recorded in the presence of Tat, and were 
exacerbated at a low pacing cycle length. Altogether, these data obtained on human K+ 
channels both in heterologous expression systems and in human cardiomyocytes strongly 
suggest that Tat sequesters PIP2, leading to a reduction of IKr and IKs, and provide a molecular 
mechanism for QT prolongation in HIV-infected patients. 
Key words:  
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1. INTRODUCTION
As a consequence of the development of antiretroviral therapies (ART), life expectancy of 
HIV-positive individuals has greatly increased. For this population, excess mortality is 
moderate in industrialized countries and comparable with populations having other chronic 
conditions [1]. Life expectancy of HIV-positive individuals has also increased in middle 
income countries, gaining for instance 10 years between 2004 and 2011 in South Africa [2]. 
Worldwide, the increasing access of patients to ART, from 31% in 2008 to 36% in 2014 [3, 4] 
leads to further increase in aging HIV-positive individuals. This aging population faces 
additional pathologies that are over-represented as compared to the general population. This is 
pointed out by a study on sudden cardiac death (SCD) in HIV positive individuals, showing a 
mean SCD rate 4.5 fold higher than in the general population [5]. Furthermore, up to 20% of 
the HIV patients are presenting with a long QT syndrome (LQTS), a greater prevalence than 
in the general population; prolonged QT interval is a risk factor for malignant arrhythmia [5-
8]. However, the mechanistic link between LQTS and HIV remains unidentified.  
Many drugs and combinations of drugs may be potential triggers of LQTS through inhibition 
of a major cardiac repolarizing current, IKr, conducted by the voltage-gated potassium channel 
hERG [9]. Among them, numerous drugs currently prescribed to HIV-positive individuals 
have been associated with a QT prolongation, such as macrolides, pentamidine, azole 
antifungals, fluoroquinolones [10] and methadone [11]. On the other hand, QT prolongation 
on ECGs of HIV-positive individuals is correlated to the duration of HIV infection rather than 
the anti-HIV treatment [12]. Moreover, QT prolongation is observed in HIV-positive 
individuals under no medication recognized to prolong QT [13], suggesting a role for the 
virus itself in inducing LQTS. In addition, several studies using animal models suggest a 
rather direct implication of HIV in LQTS. For instance, prolonged cardiac repolarization and 
decreased repolarizing potassium currents were observed in mice expressing the whole HIV-1 
genome [14, 15].  
Among the ~15 proteins encoded by the virus, Tat appears as a potential candidate for 
inducing ventricular arrhythmias, as it prolongs the action potential of guinea-pig ventricular 
cardiomyocytes through a reduction in the hERG-related current, IKr [16]. Noteworthy, serum 
levels of Tat remain high in treated patients, which could explain the high prevalence in 
prolonged QT interval despite antiretroviral therapies [12, 17]. Among the documented 
properties of Tat in cells, it was shown that its affinity for phosphatidylinositol-(4,5)-
bisphosphate (PIP2) is very high, the dissociation constant (Kd) being in the low nanomolar 
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range [18]. QT prolongation is majorly associated with the inhibition of two major cardiac 
delayed rectifier potassium currents: IKs and IKr, respectively carried by KCNQ1 channels 
associated with the regulatory subunit KCNE1 and hERG channels [19]. Interestingly enough, 
both KCNQ1 and hERG are positively regulated by PIP2 [20, 21]. We thus hypothesized that 
Tat inhibits these channels by sequestering membrane PIP2, leading to long QT syndrome in 
HIV patients.  
In order to test this hypothesis, we evaluated the effect of Tat on cells expressing KCNQ1 or 
hERG channels. Tat over-expression led to a decrease in hERG and KCNE1-KCNQ1 currents 
and modification of their biophysical parameters, in particular an acceleration of deactivation. 
A mutant Tat with a profound decrease in PIP2 affinity has no effect on these current and WT-
Tat has no effect on a PIP2 insensitive mutant KCNQ1 channel, consistent with Tat acting 
through a reduction in available PIP2. In human cardiomyocytes derived from induced 
pluripotent stem cells, 24-h Tat incubation led to a decrease in cardiac IKr and acceleration of 
its deactivation, and these effects were associated with a prolongation of the action potential 
duration. Altogether, these observations suggest that in HIV-positive individuals, Tat 
sequesters PIP2, leading to a decrease in IKr and IKs currents, providing a basis for QT 
prolongation.  
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2. MATERIALS AND METHODS
2.1. Tat protein preparation 
Recombinant Tat was purified from Escherichia coli as previously described [22], 
resuspended as a 200 µg/ml stock solution in citrate buffer (110 mM sodium chloride, 30 mM 
sodium citrate, 20 mM sodium phosphate, pH 7.3), and stored at -80°C. BCA protein assay 
(Pierce) was used to measure Tat protein concentration. Tat transactivation activity was 
confirmed as previously described [23]. Briefly, COS-7 cells were cultured in 24-well plates 
and cotransfected using FuGENE 6 (Promega) with 0.22 µg/well pGL3-LTR, encoding firefly 
luciferase under the control of Tat-activated HIV-1-LTR promoter, and 1.78 µg/well pRL-TK 
(Promega), encoding Renilla luciferase under the control of Herpes simplex virus thymidine 
kinase promoter, to normalize the results. After 24 h, 2.3 µg/ml recombinant Tat (or the 
citrate buffer) and 100 µM chloroquine (for Tat uptake) were added. One day later, cells were 
lysed for determination of dual firefly/Renilla luciferase activity ratio (Supplemental figure 
1). Twenty-four hours before patch-clamp measurements and immunofluorescence assays, Tat 
was diluted and cells were incubated at concentrations of 200 ng/ml  (~20 nM) or 400 ng/ml 
(~40 nM), consistent with patient serum levels [17].  
Supplemental figure 1: Tat protein is active in COS-7 cells. Firefly/Renilla luciferase 
activity ratio in luciferase-transfected COS-7 cells, either untreated (Buffer) or incubated with 
WT-Tat (Tat), in presence of chloroquine. Firefly luciferase expression is driven by a Tat-
dependent promoter while Renilla luciferase expression is insensitive to the presence of Tat 
and serves as an internal control. 
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2.2. Cell culture and transfection 
HEK293 cells stably expressing hERG (HEK-hERG; CreaCell; protein accession number: 
NP_000229.1) and COS-7 cells (American Type Culture Collection) were cultured in 
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% fetal calf serum 
(Eurobio) and antibiotics (100 IU/ml penicillin and 100 μg/ml streptomycin; Gibco) at 5% 
CO2 and 37°C in a humidified incubator. For HEK-hERG cells, hERG expression was 
maintained by the application of the selection antibiotic G418 (1200 µg/ml; Life 
Technologies). 
When reaching 60–80% cell confluence, COS-7 cells were transiently transfected in 35-mm 
plates with 2 μg of total DNA (as described below) complexed with FuGENE 6. For Tat and 
KCNE1-KCNQ1 co-transfection experiments, the ionic currents were obtained from a fusion 
protein of the human KCNE1 (protein accession number: AAA58418.1) linked to the N-
terminus of the human KCNQ1 (protein accession number: NP_000209.2), a kind gift of Dr 
Robert S. Kass (Columbia University, New York, USA). DNA amounts were 200 ng of 
pCDNA3.1-WT-KCNE1-KCNQ1 [21] or pCDNA3.1-KCNE1-R539W-KCNQ1 + 1.6 μg of 
bidirectional pBI-WT-Tat or pBI-W11Y-Tat or pEGFP-C1 (Clontech) + 200 ng of pUHD-
15.1 (required for expression from pBI vector [18]). For Tat and hERG co-transfection 
experiments, DNA amounts were 600 ng of pSI-hERG (protein accession number: 
NP_000229.1) [21] + 1.2 μg of pBI-WT-Tat/GFP or pBI-W11Y-Tat/GFP bidirectional 
plasmid, or pEGFP-C1 (Clontech) + 200 ng of pUHD-15.1. For Tat incubation experiments, 
DNA amounts were 600 ng of pSI-hERG + 1.4 μg of pEGFP-C1 (Clontech) or 200 ng of 
pCDNA3.1-KCNE1-KCNQ1 + 1.8 μg of pEGFP-C1 (Clontech). Cells were isolated, using 
trypsin, 24 h after transfection (of ion channels cDNA) for Tat incubation experiments or 48 h 
after transfection for Tat transfection experiments, and cultured in 35mm plastic Petri dishes. 
In the latter case, medium was renewed 8 h before cells were split. For Tat incubation 
experiments, Tat or citrate buffer diluted in culture medium were applied 4-6 hours after cells 
splitting and treated cells were incubated at 37°C. Experiments were performed the day after 
cell splitting.  
2.3. Culture of human induced pluripotent stem cells 
The previously characterized foreskin fibroblast-derived human induced pluripotent stem 
(hiPS) cell clone C2a was used [24]. The hiPS cell line was maintained on mitotically-
inactivated MEFs in DMEM/F12 medium supplemented with 2 mM L-glutamine, 0.07% β-
mercaptoethanol, 20% knockout serum replacement, 5 ng/ml bFGF and 1% NEAA under low 
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oxygen atmosphere (4% O2). Cells were passaged by manual dissection of cell clusters every 
6 to 7 days. Before cardiac differentiation, hiPS cells were manually transferred from MEFs 
to hESC-qualified matrigel-coated plates (0.05 mg/ml, BD Biosciences) and cultured in 
StemMACS (iPS-Brew XF) medium (Miltenyi Biotec). Passages were performed using 
Gentle Cell Dissociation Buffer (StemCell Technologies). 
 
2.4. Differentiation of hiPS cells into cardiomyocytes and dissociation 
Human iPS cells were differentiated into cardiomyocytes using the Matrix sandwich method, 
as previously described [25, 26]. Cardiomyocytes derived from hiPS cells (hiPS-CMs) were 
dissociated around day 20 of differentiation, for 20 min in collagenase II (200 U/ml; Gibco) at 
37°C. Isolated cells were then incubated at room temperature for 30 min in Kraft-Bruhe 
solution containing (in mmol/L): KCl 85, K2HPO4 30, MgSO4 5, EGTA 1, Na2-ATP 2, Na-
pyruvate 5, creatine 5, taurine 20, and glucose 20, pH 7.2 [27]. For Tat immunofluorescence 
studies, dissociated hiPS-CMs were plated on IBIDI plates (Biovalley). Beating hiPS-CMs 
were cultured in RPMI1640 medium supplemented with B27 complete (Life Technologies) 
and 1% NEAA and changed every other day and used between day 10 and day 14 post-
dissociation. 
 
2.5. Single-cell electrophysiology in COS-7 and HEK-hERG cells 
In HEK-hERG and transfected COS-7 cells, currents were recorded at room temperature 
using the patch-clamp technique. The cells were continuously superfused with a HEPES 
buffered Tyrode solution containing (in mmol/L): NaCl 145, KCl 4, MgCl2 1, CaCl2 1, 
HEPES 5, glucose 5, pH adjusted to 7.4 with NaOH. For K+ current recordings, pipettes 
(Kimble Chase; tip resistance: 1.8 to 2.5 MΩ) were filled with an intracellular medium 
containing (in mmol/L): KCl 100, Kgluconate 45, MgCl2 1, EGTA 5, HEPES 10, pH adjusted 
to 7.2 with KOH. All products were purchased from Sigma. Stimulation and data recording 
were performed with Axon pClamp 10 through an A/D converter (Digidata 1440A) using an 
Axopatch 200B (all Molecular Devices). hERG current (IhERG) density was measured using a 
depolarization from -80 mV to +60 mV for 2 s and repolarization to -40 mV for 2 s where the 
tail current was measured (stimulation frequency: 0.125 Hz). Activation curve was obtained 
by a series of 2-s depolarizations from -80 to +50 mV (same holding potential and frequency 
as above, increment: 10 mV) followed by a 2-s repolarization to -40 mV. Inactivation was 
studied with a three-pulse protocol: a 1-s depolarization from -80 mV to +40 mV was 
followed by a 15-ms repolarization to potentials ranging from +30 to -130 mV and a 500-ms 
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depolarization to +40 mV where the remaining current was measured (0.2 Hz). Kinetics of 
deactivation were evaluated by a two-exponential regression of the decaying current recorded 
at various potentials from -70 to -130 mV (3-s duration), after a 2-s depolarization from -80 
mV to +40 mV (0.125 Hz). The same protocol was used to evaluate the recovery from 
inactivation kinetics by fitting the rising phase of the current, before deactivation, with a 
single exponential function. Finally, inactivation kinetics were studied with another three-
pulse protocol: a 1-s depolarization from -80 mV to +60 mV was followed by a 25-ms 
repolarization to -110 mV and 500-ms-depolarizations to potentials ranging from +60 to -60 
mV where the inactivating current was fitted with a single exponential function (0.2 Hz). 
KCNE1-KCNQ1 current density was measured using depolarizations from a holding potential 
of -80 mV to various potentials from -60 mV to +80 mV for 4 s (or from -60 mV to +120 mV 
when comparing WT-Tat effect on WT KCNE1-KCNQ1 and KCNE1-R539W-KCNQ1) and 
repolarization to -40 mV for 1.2 s where the tail current was measured (increment: 20 mV, 
stimulation frequency: 0.125 Hz). Fit of the non-normalized activation curves was used to 
estimate full-activated KCNE1-KCNQ1 current density for each cell. 
 
2.6. Action potential, IKr, and ICa,L recordings in cardiomyocytes derived from hiPS 
cells 
Before recording, cells were incubated for 24 h either with citrate buffer or with 200 ng/ml 
(20 nmol/L) of Tat protein. Cells were continuously superfused with a cardiomyocyte Tyrode 
solution containing (in mmol/L): NaCl 140, KCl 4, CaCl2 1, MgCl2 0.5, glucose 10, HEPES 
10; pH 7.4 (NaOH) at 35 ± 2°C as previously described [26].  
For action potential (AP) recording the permeabilized-patch configuration was used. The 
pipette (Sutter; tip resistance: 2 to 3 MΩ) solution contained (in mmol/L): K-gluconate 125, 
KCl 20, NaCl 5, amphotericin B 0.85x10-3, HEPES 5; pH 7.2 (KOH). APs were recorded at 
spontaneous rate or stimulated by 1.3-1.5 ms current pulses of 300-1500 pA at various pacing 
cycle lengths. APs were classified as nodal-, atrial- and ventricular-like, based on their 
duration, maximum upstroke velocity (dV/dtmax), peak to peak duration, amplitude (mV) and 
maximum diastolic potential, as previously defined [26]. 
For currents recording, the ruptured-patch configuration was used.  
For IKr recording, the pipette was filled with a solution containing (in mmol/L): K-gluconate 
125, KCl 20, HEPES 10, EGTA 10; pH 7.2 (KOH). A local gravity microperfusion system 
allowed application of 4 µmol/L nifedipine to block ICa,L and 1 µmol/L E-4031 to block IKr 
[28], dissolved in cardiomyocyte Tyrode solution plus mannitol 30 mmol/L. 
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IKr tail current density was measured as the E-4031-sensitive current using a depolarization 
from -50 mV to +60 mV for 4 s and repolarization to -50 mV where the tail current was 
measured (stimulation frequency: 0.08 Hz). Activation was evaluated by a series of 4-s 
depolarizations from -60 to +20 mV (holding potential: -50 mV, increment: 10 mV, same 
frequency as above) followed by a repolarization to -50 mV. Deactivating currents were fitted 
by a standard bi-exponential function.  
ICa,L was recorded at room temperature. Wax-coated pipettes were filled with an intracellular 
medium containing (in mmol/L): CsCl2 145, NaCl 5, CaCl2 2, MgATP 5, EGTA 5, HEPES 
10, pH adjusted to 7.2 with CsOH. During recording, the microperfusion system allowed 
application of an extracellular solution containing (in mmol/L): TEA-Cl 160, CaCl2 5, MgCl2 
1, glucose 10, HEPES 10, TTX 0.01, mannitol 20; pH 7.4 (CsOH).  
ICa,L I/V curve was evaluated by a series of 200-ms depolarizations from a 3-s pre-pulse to -50 
mV to potentials ranging from -60 to +50 mV (increment: 5 mV, stimulation frequency: 0.125 
Hz) followed by a repolarization to the holding potential at -80 mV. Inactivation was studied 
with a two-pulse protocol: a 3-s depolarization to potentials ranging from -65 to -5 mV was 
followed by a 400-ms depolarization to 0 mV where the peak current was measured (holding 
potential: -50 mV, 0.125 Hz). 
2.7.IKATP recordings in mouse neonatal cardiomyocytes
Single cell suspensions from 1-2 day-old mouse neonatal hearts were prepared in a semi-
automated procedure by using the Neonatal Heart Dissociation kit and the gentleMACSTM 
Dissociator. Hearts were first excised from the mice then the ventricles were separated from 
the atrium. After gentleMACSTM dissociation, the cell supernatant was removed by 
centrifugation and the pellet was resuspended in culture medium containing Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% horse serum, 5% fetal bovine 
serum and penicillin (100U/mL)/ streptomycin (100 Pg/mL), then the cells were plated on 65 
mm diameter Petri dish (NuncTM). After 2h of initial plating, myocytes were resuspended in 
the same culture medium and plated on 35 mm diameter Petri dishes at a density of 6 x 104 
cells per plate. Myocytes were maintained in culture for 48 hours. 
Cells were continuously superfused with a cardiomyocyte Tyrode solution, as above, at 35 ± 
2°C. The pipette was filled with a solution containing (in mmol/L): K-aspartate 85, KCl 44, 
Na-pyruvate 5, HEPES 10, EGTA 0.01; MgCl2 3; pH 7.2 (KOH). During recording, a local 
gravity microperfusion system allowed application of 20 µmol/l glibenclamide [28], dissolved 
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in an extracellular solution containing (in mmol/L): NaCl 140, KCl 4, CoCl2 1, MgCl2 0.5, 
mannitol 30, HEPES 10; pH 7.4 (NaOH). From a holding potential of -70 mV, followed by a 
20-ms step to -20mV, current was measured at the end of a 350 ms pulse to +40 mV (0.2 Hz). 
After patch rupture, the outward current increased gradually due to dilution of cytosolic ATP 
into the pipette. When the current reached steady state, glibenclamide was added to the 
external solution to block the IKATP current. A ramp protocol was used to monitor the current 
decrease upon glibenclamide application. From a holding potential of -70 mV, a 20 ms step to 
-110 mV was applied followed by a 500 ms ramp from -110 to +40 mV (stimulation 
frequency, 0.2 Hz). A step protocol was applied before and after glibenclamide application to 
measure the glibenclamide-sensitive current.  
2.8. Tat immunofluorescence 
Two types of histological analyses were performed, (1) one to study localization of 
transfected Tat in COS-7 cells, (2) another to study localization of incubated Tat in both COS-
7 and hiPS-CMs. (1) COS-7 cells were transfected with hERG and either WT- or W11Y-
Tat/GFP bidirectional plasmids as for patch-clamp experiments. Forty eight hours after 
transfection, cells were plated on IBIDI plates for 24h. (2) COS-7 cells were transfected with 
hERG plasmid only, and forty eight hours after transfection, cells were plated on IBIDI plates. 
Both COS-7 cells and dissociated hiPS-CMs were then incubated with Tat protein at 
200ng/ml for 24h.  
Cells were fixed with 3.7% formaldehyde, permeabilized with 0.5% saponin and blocked with 
1% PBS-BSA. All cells were then stained with mouse monoclonal antibody directed against 
HIV-1 Tat (SC-65912, Santa Cruz) and cells incubated with Tat were co-stained with goat 
polyclonal antibody directed against hERG (SC-15968, Santa Cruz) diluted in PBS. For all 
immunostainings, secondary antibody staining was performed using respectively Alexa 568 
conjugated anti-mouse antibody and Alexa 488 conjugated anti-goat antibody (Molecular 
Probes). DAPI was used for nuclear staining. For Tat-transfected COS-7 cells, GFP was 
directly observed. Conventional imaging was performed using Nikon Confocal A1RSi and 
Super-resolution imaging using N-SIM (Structured Illumination Microscopy) microscope 
system (Nikon) equipped with a SR Apo 100 × 1.49 N.A. 
2.9. mRNA and Protein expression analysis 
For gene expression analysis, total RNA was extracted and reverse transcribed, from hiPS-
CMs and HEK-hERG cells, as previously described [26]. PCR amplification was performed 
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using FAM-labeled TaqMan probes: ACTB (Hs99999903_m1), KCNH2 (Hs04234270-g1) 
and Troponin I (Hs00165957-m1). 
For Western blot analysis, 60 µg of protein lysate from hiPS-CMs or 10 µg of protein lysate 
from HEK-hERG, both treated for 24 h with 200 ng/ml Tat or buffer were incubated with 
mouse antisera against hERG protein (Santa Cruz). Secondary antibody staining was 
performed using goat anti-mouse IgG-HRP antibody (Santa Cruz). Stain Free gel technology 
(Bio-Rad) was used as loading control for protein normalization: the amount of total proteins 
in each lane of the blot was calculated and used for normalization [29, 30]. 
 
 
2.10.  Data analysis 
Steady-state activation and inactivation curves were fitted with a single Boltzmann function 
using GraphPad Prism 5.02. Data are presented as mean ± SEM when normally distributed or 
Tukey boxplots (Q1-Q3 boxes) when not. Statistical significance was estimated using 
Student's t-test, Mann-Whitney test, or two-way ANOVA for repeated measures when 
appropriate. Post-hoc test for multiple comparison (Holm-Sidak method) was performed when 
needed. A value of p < 0.05 was considered as the threshold for statistical significance. 
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3. RESULTS 
3.1.  Tat transfection leads to a decrease in hERG and KCNE1-KCNQ1 currents 
and acceleration of deactivation, consistent with a decrease in PIP2 availability 
We first evaluated the effects of Tat co-expression with hERG or KCNQ1 fused to KCNE1 
(KCNE1-KCNQ1) in COS-7 cells. This set of experiments allowed us to compare the effects 
of WT-Tat with those of W11Y-Tat, which presents a profoundly reduced PIP2 affinity, 
although having a normal transactivation activity [18]. In contrast with WT-Tat, this mutant 
cannot enter the cells and thus, testing the effects of its intracellular application requires its 
transfection. Figure 1A shows representative hERG current recordings in cells co-transfected 
with GFP, WT-Tat, or W11Y-Tat. IhERG density was reduced in presence of WT-Tat as 
compared to GFP. In order to test whether this is due to a reduction in PIP2 availability, we 
evaluated the effects of the W11Y-Tat. Consistent with the hypothesis, we did not observe 
any alteration of the hERG current. It was shown that a decrease in PIP2 leads to a 
destabilization of hERG open state, provoking a reduction in the current amplitude and an 
acceleration in channel deactivation without any shift of the activation curve to positive 
potentials [21]. In accordance with a PIP2-reduction effect, WT-Tat and not W11Y-Tat led to 
the same changes in current density and deactivation without any shift in the activation curve 
(Figure 1B-D, Table 1). These data suggest that Tat inhibits hERG by sequestering PIP2. 
For KCNE1-KCNQ1 also, a decrease in PIP2 availability leads to a decrease in current density 
and an acceleration of deactivation [20]. Again, WT-Tat but not W11Y-Tat led to the same 
effects as when the channel interaction with PIP2 is altered (Figure 1E-H, Table 1). To 
confirm the hypothesis that Tat reduces the current amplitude of delayed rectifier currents 
through a decrease in available PIP2, we tested the effect of Tat on the mutant KCNE1-
R539W-KCNQ1 channel that is insensitive to PIP2 depletion, when triggered by wortmannin 
application or by CiVSP phosphatase activation [31]. We compared current amplitude in cells 
expressing KCNE1-R539W-KCNQ1 in the absence and presence of Tat (Figure 2). As 
opposed to WT KCNE1-KCNQ1, Tat expression did not affect KCNE1-R539W-KCNQ1 
current amplitude measured after channel full activation, reinforcing the interpretation that 
Tat decreases KCNE1-KCNQ1 channel activity through a decrease in available PIP2. 
Altogether, these data strongly suggest that Tat inhibits hERG and KCNE1-KCNQ1 currents 
by sequestering PIP2. 
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Figure 1: Tat transfection alters hERG and KCNE1-KCNQ1 currents in COS-7 cells. 
(A) Representative superimposed current recordings in COS-7 cells co-transfected with 
hERG, and either GFP, WT-Tat/GFP or W11Y-Tat/GFP, a mutant with reduced PIP2 affinity. 
(B) Tukey boxplots presenting hERG maximal tail current densities; (C) activation curves and 
(D) time constants of deactivation (fast and slow) versus voltage in the same conditions as in 
A. The fast component represents 80 to 90% of the deactivating current, depending on the 
potential, with no effect of Tat. (E) Representative current recordings in COS-7 cells co-
transfected with KCNE1-KCNQ1, and either GFP, WT-Tat/GFP or W11Y-Tat/GFP. (F) 
Tukey boxplots presenting KCNE1-KCNQ1 maximal tail current densities; (G) activation 
curve and (H) time constants of deactivation at -40 mV in the same conditions as in E. 
Current densities differences were statistically evaluated using a Mann-Whitney test, hERG 
τdeact using a two-way ANOVA for repeated measurements, and KCNE1-KCNQ1 τdeact at -40 
mV using Student t-test. * p < 0.05; for WT-Tat vs GFP. # p < 0.05; ## p < 0.01; ### p < 
0.001 for W11Y-Tat vs WT-Tat. § p < 0.05. 
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Table 1: Tat transfection alters hERG and KCNE1-KCNQ1 currents in COS-7 cells: 
biophysical characteristics.  
Tat transfected 
COS-7 hERG COS-7 KCNE1-KCNQ1 
GFP WT-Tat W11Y-Tat GFP WT-Tat W11Y-Tat 
Current density (32) (46) (43) (15) (21) (15) 
at 60 mV 
(pA/pF) 62.6 ± 9.5 31.2 ± 3.9*  72.6 ± 10.4
### 42.2 ± 13.1 13.0 ± 3.9*  46 ± 10.3##  
Activation (18) (29) (28) (12) (12) (14) 
V1/2 (mV) -10.2 ± 1.7 -11.1 ± 1.5 -8.98 ± 1.6 24.6 ± 2.3 29.9 ± 2.3 26.6 ± 1.9 
K (mV) 7.6 ± 0.3 6.8 ± 0.1**  7.1 ± 0.1 13.4 ± 0.7 13.5 ± 0.6 13.9± 0.4 
 
(n): number of cells; Student t-test, *: p < 0.05, **: p < 0.01 vs GFP; ##: p < 0.01; ###: p < 
0.001 vs WT-Tat; V1/2 and K: voltage for half-activation or -inactivation of the K+ currents 
and slope. 
 
 
Figure 2: Tat transfection does not alter the PIP2 insensitive mutant KCNE1-R539W-
KCNQ1 currents in COS-7 cells. (A) Representative superimposed current recordings in 
COS-7 cells co-transfected with KCNE1-R539W-KCNQ1, and either GFP (left) or WT-
Tat/GFP (right). (B) Tukey boxplots presenting WT-Tat effect on WT (left) or KCNE1-
R539W-KCNQ1 (right) maximal tail current densities, using the same stimulation protocol as 
in A (depolarization up to +120 mV); (C) activation curve in the same conditions as in A. 
Current densities differences were statistically evaluated using a Mann-Whitney test. ** p < 
0.01. 
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To localize Tat, immunofluorescence assays were performed using the same conditions as for 
patch-clamp experiments, i.e. cotransfection of hERG with either WT- or W11Y-Tat/GFP 
bidirectional plasmids. They confirmed that WT-Tat localizes at the COS-7 plasma 
membrane, through its interaction with PIP2 [32]. Unlike WT-Tat, W11Y-Tat localized 
diffusely in the cytosol, its lack of affinity for PIP2 preventing its plasma membrane 
localization (Figure 3A & B). This is consistent with the absence of W11Y-Tat effect on PIP2-
dependent channels activity. 
 
Figure 3: WT-Tat but not W11Y-Tat localizes at the plasma membrane in COS-7 cells. 
(A) Representative confocal immunostainings of, in red, WT-Tat or W11Y-Tat in transfected 
COS-7 cells. GFP is used as a transfection reporter. Nuclei are stained with DAPI. Scale = 10 
µm. (B) Surface plots of Tat, GFP and DAPI fluorescence intensities in each cell at the level 
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of the drawn lines in A. Higher WT-Tat densities are observed in the region of the plasma 
membrane, as opposed to W11Y-Tat. 
3.2. Tat incubation does not alter hERG and KCNE1-KCNQ1 currents in 
heterologous expression systems 
In HIV patients, T-cells-secreted Tat can enter multiple cell types, through the interaction 
with various ubiquitous receptors [18]. We thus tested the effect of Tat applied externally on 
hERG and KCNE1-KCNQ1 channels activity. We first studied the effect of Tat 24-h 
incubation in HEK293 cells stably expressing hERG channels. We chose a 24-h incubation 
since in the different biological assays in which Tat had been tested (neurosecretion [32] and 
phagocytosis [33]), it was found to require some time (3-4 hours) for Tat, after initial 
internalization, to accumulate on PIP2 and to perturb processes relying on this 
phosphoinositide. Moreover such a 24-h incubation, and not acute application, had already 
been associated with a decrease in hERG current density in this model [16]. Surprisingly and 
unlike the previous observations, Tat incubation (200 or 400 ng/ml) did not induce any 
change (Supplemental figure 2A; Supplemental table 1). In addition, neither activation nor 
inactivation curves were modified by Tat incubation (Supplemental figure 2B & D; 
Supplemental table 1), nor the kinetics of deactivation, inactivation and recovery from 
inactivation (Supplemental figure 2C, E & F). In addition, neither mRNA nor total hERG 
protein levels were affected (Supplemental figure 2G & H). Tat entry into cells occurs 
through receptors of which expression vary from one cell type to another [34]. The observed 
absence of Tat effect may then be due to insufficient penetration into HEK cells. In order to 
evaluate whether the cell type could explain the absence of incubated Tat effect on IhERG, this 
analysis was repeated in COS-7 cells transiently expressing hERG (Supplemental figure 3). 
Again 200 ng/ml Tat incubation did not lead to any change in either hERG current density or 
biophysical parameters. In addition, we did not observe any effect of Tat incubation on 
KCNE1-KCNQ1 channel activity in COS-7 cells (Supplemental figure 4). 
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Supplemental table 1: Tat incubation has no effect on hERG and KCNE1-KCNQ1 
currents in heterologous expression systems: biophysical characteristics.  
Tat incubated 
HEK-hERG COS-7-hERG COS-7-KCNE1-KCNQ1 
Buffer Tat 200 ng/ml 
Tat 400 
ng/ml Buffer 
Tat 200 
ng/ml Buffer 
Tat 200 
ng/ml 
Current density (23) (14) (14) (38) (35) (19) (19) 
at 60 mV 
(pA/pF) 19.5 ± 2.0 23.3 ± 3.7  18.9 ± 2.9  54.6 ± 10.9 39.9 ± 7.3 31.7 ± 7.5 42.0 ± 8.6 
Activation (16) (11) (12) (18) (22) (11) (11) 
V1/2 (mV) -26.9 ± 1.4 -25.0 ± 2.8 -26.6 ± 1.4 -11.1 ± 1.4 -15.1 ± 1.8 26.6 ± 4.6 26.7 ± 4.3  
K (mV) 7.4 ± 0.2 7.6 ± 0.3 7.5 ± 0.1 7.0 ± 0.3 6.5 ± 0.2 16.6 ± 1.4 15.4 ± 0.6 
Inactivation (12) (5) (8) (8) (6)     
V1/2 (mV) -66.3 ± 1.4 -67.2 ± 3.2 -71.0 ± 2.1 -54.6 ± 7.3 -57.3 ± 2.4 - - 
K (mV) 20.7 ± 0.4 20.9 ± 0.5 20.3 ± 0.7 22.6 ± 0.6 20.4 ± 0.7 - - 
(n): number of cells; Student t-test. V1/2 and K: voltage for half-activation or -inactivation of 
the K+ currents and slope. 
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Supplemental figure 2: Tat incubation has no effect on hERG current in HEK-hERG 
cells. (A) Tukey boxplots presenting hERG tail current densities incubated with buffer, 200 
ng/ml or 400 ng/ml WT-Tat (Tat). (B) Activation curve measured from the tail current 
densities; (C) time constants of deactivation (fast and slow) versus voltage; (D) inactivation 
curve; (E) time constants of inactivation versus voltage; (F) time constants of recovery from 
inactivation versus voltage in the same conditions as A. The protocols used are shown as 
insets. The same protocol is used for (C) and (F). (G) hERG mRNA expression level versus 
ACTB mRNA. (H) Top left: Western blot analysis of hERG protein expression in HEK-
hERG cells. Two hERG specific bands were revealed (mature, glycosylated membrane 
subunit, 155 kDa, and immature, non-glycosylated cytoplasmic subunit, 135kDa). Top right: 
Stain-free expression served as internal control of gel loading. Bottom: Normalized intensity 
quantification of the total and mature hERG bands. 
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Supplemental figure 3: Tat incubation has no effect on hERG current in transfected 
COS-7 cells. (A) Tukey boxplots presenting hERG tail current densities recorded from cells 
incubated with buffer or 200 ng/ml WT-Tat (Tat). (B) Activation curves measured from the 
tail currents; (C) time constants of deactivation (fast and slow) versus voltage; (D) 
inactivation curves; (E) time constants of inactivation versus voltage; (F) time constants of 
recovery from inactivation versus voltage in the same conditions as A. The protocols used are 
shown as insets. The same protocol is used for (C) and (F).  
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Supplemental figure 4: Tat incubation has no effect on KCNE1-KCNQ1 current in 
transfected COS-7 cells. (A) Representative current recordings in COS-7 cells transfected 
with KCNE1-KCNQ1, and incubated with either buffer or 200 ng/ml WT-Tat (Tat; voltage 
protocol in B). (B) Tukey boxplots presenting KCNE1-KCNQ1 tail current densities; (C) 
activation curves and (D) time constants of deactivation at -40 mV in the same conditions as 
in A.  
 
3.3. Tat incubation decreases IKr in cardiomyocytes derived from human induced 
pluripotent stem cells 
Cardiomyocytes differentiated from hiPS cells provided us with the opportunity to evaluate 
the effect of Tat incubation on a more relevant cellular model than non-cardiac cells. As 
shown in figure 4A & B, IKr, isolated as the E-4031-sensitive current, was significantly 
reduced in hiPS-CMs incubated for 24 h with 200 ng/ml Tat. After full activation, the 
maximum tail E-4031-sensitive current density measured at -50 mV was reduced by 31% 
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(Figure 4B; Table 2; p < 0.05). In addition, no detectable IKs was observed after E-4031-
application. Thus, activation curve and deactivation kinetics were measured using the total K+ 
tail current. The activation curve was not modified but the current deactivation was 
accelerated (Figure 4C & D; Table 2, p < 0.05). Therefore, we observed similar effect of Tat 
on the activation gate as compared to the experiments in Tat-transfected COS-7 cells, 
reminiscent of the effect of a decrease in PIP2. This suggests that hiPS-CMs express receptors 
allowing Tat integration in sufficient quantity to alter the currents, as opposed to COS-7 and 
HEK293 cellular models. We directly tested this hypothesis using confocal and Structured 
Illumination Microscopy (SIM) imaging on Tat-incubated COS-7 cells expressing hERG, and 
hiPS-CMs. Confocal images showed that Tat protein was comparably present in both cell 
types after 24h incubation (Figure 5A). Higher magnification analyses highlighted that in 
COS-7 cells expressing hERG, Tat protein did not enter the cells. In marked contrast, in hiPS-
CMs, Tat was found both in the cytoplasm and/or vesicular structures that are presumably 
endocytic elements as well as colocalized with hERG proteins, at the plasma membrane 
(Figure 5B). Altogether, these experiments in hiPS-CMs show that Tat, when applied at 
biologically relevant concentrations is able to affect PIP2 availability, thereby affecting IKr 
current.  
Since Tat also affects transfected KCNE1-KCNQ1, which is related to the cardiac IKs current, 
we set out to study the effect of Tat on IKs in native tissue. However, in our model of 
cardiomyocytes differentiated from hiPS cells, we did no observe any tail current in presence 
of 1 µM E-4031 (not shown), suggesting that KCNE1 and/or KCNQ1 subunits are not 
expressed/functional in this model. We also applied 1 µM epinephrine to enhance this current 
[35, 36] but again, no tail was observed in 1 µM E-4031. 
Table 2: Tat reduces IKr recorded from hiPS-CMs: biophysical characteristics.  
Tat incubated 
iPS-CMs-IKr 
Buffer Tat 200 ng/ml 
Current density (15) (15) 
at 60 mV 
(pA/pF) 0.93 ± 0.18 0.64 ± 0.23*  
Activation (21) (13) 
V1/2 (mV) -23.7 ± 1.6 -22.7 ± 1.7 
K (mV) 5.7 ± 0.5 5.7 ± 0.4 
(n): number of cells; Student t-test, *: p < 0.05; V1/2 and K: voltage for half-activation or 
-inactivation of the K+ currents and slope. 
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Figure 4: Tat reduces IKr recorded from hiPS-CMs. (A) Representative superimposed 
currents recorded from hiPS-CMs incubated with buffer (left) or 200 ng/ml WT-Tat (Tat; 
right), before (control) and after 1 µM E-4031 application. The E-4031-sensitive current, IKr, 
was obtained by digital subtraction of the current recorded after E-4031 application to the one 
recorded before application (inset: voltage-clamp protocol). (B) Tukey boxplots presenting IKr 
tail current density measured at -50 mV after depolarization at +60 mV. Mann-Whitney test: * 
p < 0.05. (C) IKr activation curves measured from the tail currents. (D) Averaged time 
constants of fast and slow deactivation upon repolarization at -50 mV. Student t-test: * p < 
0.05. The fast component represents around 50% of the deactivating current in both 
conditions. (E) hERG mRNA expression level versus Troponin I mRNA. (F) Top left: 
Western blot analysis of hERG protein expression in hiPS-CMs. Two hERG specific bands 
were revealed (mature, glycosylated membrane subunit, 155 kDa, and immature, non-
glycosylated cytoplasmic subunit, 135kDa). Top right: stain-free expression served as internal 
control of gel loading. Bottom: normalized intensity quantification of the total and mature 
hERG bands in hiPS-CMs. Student t-test: * p < 0.05. 
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Figure 5: Tat enters hiPS-CMs but not COS-7 cells. (A) Representative confocal 
immunostainings of Tat (red) and hERG (green). Left: COS-7 cells expressing hERG. Right: 
hiPS-CMs. Top: cells incubated with control buffer. Bottom: cells incubated with Tat. Scale = 
50 Pm. (B) Top: Representative confocal immunostainings of Tat-incubated COS-7 cells and 
hiPS-CMs. Bottom: Representative SIM immunostainings, showing that Tat remains in the 
extracellular compartment of COS-7 cells (red arrow) while in hiPS-CMS, Tat is located 
inside the cytoplasm (asterisks) and colocalizes with hERG at the plasma membrane (yellow 
arrows). Scale = 5 Pm. 
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In addition to hERG and KCNQ1, PIP2 has been shown to modulate the activity of a plethora 
of ion channels [37], yet it is possible that many of these channels are not affected by PIP2 if 
variations are limited to its physio/pathophysiological range [38]. To address this issue, we 
tested the effect of Tat on several channels suggested to be regulated by PIP2. PIP2 has 
previously been shown to modulate the L-type Ca2+ current, ICa,L, in neurons and in natural 
killer cells [39, 40] and CaV1.2 and CaV1.3 in heterologous expression system [41]. We 
investigated Tat effects on the L-type Ca2+ current in hiPS-CMs. Tat incubation did not 
modify ICa,L density or biophysical properties (Figure 6), showing that endogenous Ca2+ 
channels activity is not affected by Tat in hiPS-CMs. This observation suggests that hiPS-CM 
Ca2+ channels are not as sensitive as hERG to a decrease in available PIP2.  
 
Figure 6: Tat has no effect on ICa,L recorded in hiPS-CMs. (A) Representative 
superimposed currents recorded from hiPS-CMs incubated with buffer or 200 ng/ml WT-Tat 
(Tat). (B) Current density-voltage relationship. Inset: protocol used (C) ICa,L activation curves 
obtained from current density-voltage curves. (D) Voltage-dependence of inactivation. Inset: 
protocol used. 
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In order to evaluate if Tat also alters the activity of an inward rectifier channel, we chose a 
channel which has a low apparent affinity to PIP2. Such channel, which is less stabilized by 
PIP2 is more prone to a decrease in activity when available PIP2 is decreased [42]. Thus we 
selected the KATP channel, since the alpha-subunit of this channel, Kir6.2, has a low affinity to 
PIP2 and is more prone to be sensitive toTat [42]. As no KATP current was detected in the 
hiPS-CMs as a glibenclamide-sensitive outward current measured at +40 mV, we used 
neonatal mouse cardiomyocytes, in which a 24 h incubation with 200 ng/ml Tat led to a 
decrease in the KATP current (Supplemental figure 5). This suggests that Tat may lead to a 
remodeling of the electrical activity of cardiomyocytes through an alteration of the activity of 
several PIP2-sensitive channels.  
 
 
Supplemental figure 5: Tat induces a decrease in IKATP recorded in mouse neonatal 
cardiomyocytes. (A) & (B). Representative superimposed currents recorded from hiPS-CMs 
incubated with buffer (A) or 200 ng/ml WT-Tat (B), during 20 µmol/l glibenclamide 
perfusion. Vertical bar, 500 pA. For clarity, only every other trace is shown. (C) Tukey 
boxplots presenting IKATP current density measured as the glibenclamide-sensitive current 
measured at the end of a 350 ms pulse to +40 mV. Mann-Whitney test: * p < 0.05.  
 
3.4. Tat related reduction of IKr is not due to a reduction in membrane hERG  
Since Tat has been shown to interfere with protein expression in host cells [43], it may also 
act on hERG through a reduction in its expression. To test whether Tat directly alters 
expression of native hERG in hiPS-CMs, we performed qRT-PCR and western blot analyses. 
While no reduction of hERG mRNA was observed, total hERG protein amount was reduced 
by about 20% only (Figure 4 E & F). Moreover, the mature (i.e. glycosylated) fraction 
responsible for the K+ current [44], was not significantly reduced (Figure 4F), suggesting that 
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inhibition of hERG protein expression is not responsible for hERG current decrease and that 
in cardiomyocytes, Tat incubation mostly affects hERG gating.  
3.5. Tat modifies the electrical activity of cardiomyocytes derived from human induced 
pluripotent stem cells 
Action potentials (APs) were then recorded using the permeabilized patch configuration in 
hiPS-CMs. Three types of AP shapes were obtained and categorized as nodal-, atrial-, and 
ventricular-like APs (Table 3). Since LQTS is associated with ventricular AP prolongation, 
we focused on ventricular-like APs paced at two cycle lengths. As illustrated in Figure 7A, 
APs were prolonged in hiPS-CMs incubated for 24 h with 200 ng/ml Tat. Only APD70 and 
APD90 were prolonged as expected with hERG inhibition (p < 0.05; Figure 7B). In addition, 
most Tat-incubated cells showed a higher APD90 dispersion compared to cells incubated with 
buffer (Figure 8). This dispersion resulted from AP duration and amplitude alternans (Figure 
8A). APD90 alternans were exacerbated at faster stimulation rates (shorter PCLs; Figure 8B).  
 
Table 3: Quantitative parameters used for classification of action potentials obtained 
from patch-clamp experiments on control cells. 
MDP: Maximum diastolic potential. dV/dt max : maximum upstroke velocity.  
 
 
 
 
hiPS-CM 
APs 
AP amplitude 
(mV) MDP (mV) 
Peak to peak  
duration (ms) 
dV/dt max 
(V/s) 
APD90 
(ms) 
(APD30–
APD40)/ 
(APD70–
APD80) 
APD50/ 
APD90 
Nodal-like 
(n=4) 63.0 ± 4.4 -41.7 ± 3.7 650.1 ± 147 2.1 ± 0.4 
174.4 ± 
2.5 2.3 ± 0.2 
0.6 ± 
0.002 
Atrial-like 
(n=7) 77.3 ± 2.2 -47.2 ± 1.5 901.2 ± 188.5 4.4 ± 0.5 
215.9 ± 
22.9 1.0 ± 0.1 
0.6 ± 
0.001 
Ventricular-
like 
(n=9) 
102.6 ± 3.1 -58.6 ± 2.1 1301.2 ± 310.8 10.9 ± 1.2 269.4 ± 30.1 4.9 ± 0.7 
0.8 ± 
0.02 
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Figure 7: Tat significantly increases ventricular-like action potential durations in hiPS-
CMs. (A) Left, representative ventricular-like APs recorded from hiPS-CMs incubated with 
buffer or 200 ng/ml WT-Tat (Tat), stimulated at a pacing cycle length (PCL) of 700 ms. 
Right, expanded APs tagged z in left panel. Horizontal dashed lines and bars: 0 mV. Vertical 
dashed lines stress the duration differences. (B) Averaged AP duration at 30 (APD30), 50 
(APD50), 70 (APD70) and 90% (APD90) of full repolarization measured in ventricular-like 
cells incubated with buffer or WT-Tat at 2 different PCLs. * : p < 0.05 (Holm-Sidak post-hoc 
test).  
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Figure 8: Tat incubation leads to alternans events in ventricular-like hiPS-CMs. (A) 
Representative ventricular-like action potentials recorded from three different hiPS-CMs 
incubated with 200 ng/ml WT-Tat (Tat). Cell 1: APD90 of five consecutive APs are indicated 
below. (B) Poincaré plots of APD90 (one color per cell) recorded at three different PCLs. The 
graphs show APD90 of each AP (number n+1) versus the APD90 of its preceding one (n). 
Same color code used in A. 
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DISCUSSION 
HIV Tat binds PIP2 with a very high affinity, the Kd being 20 to 50 times lower than the Kd of 
the phospholipase C pleckstrin homology domain, one of the best cellular ligands for PIP2 
[18]. Knowing that hERG and KCNQ1 currents are modulated by membrane PIP2 levels, we 
tested whether Tat can affect those currents by sequestering PIP2. Co-transfecting Tat with 
either channel led to modification of the biophysical parameters in accordance with a decrease 
in available PIP2. Moreover, the W11Y-Tat mutant, which is 300 times less affine for PIP2 
[18], has no effect on the activity of both channels. Importantly, W11Y-Tat mutation does not 
alter its native transactivation activity [23], suggesting that loss of effect of W11Y-Tat on 
hERG and KCNE1-KCNQ1 channels activity is rather due to the disrupted interaction with 
PIP2 than through another mechanism, such as the regulation of gene expression. Since 
W11Y-Tat is not localized to the membrane, one might argue that WT-Tat effects may be 
mediated through alternative mechanisms independent of PIP2, such as a direct interaction 
with the ion channels of interest. However, a KCNE1-KCNQ1 mutant which is not sensitive 
to PIP2 is not affected by WT-Tat, confirming that Tat acts by sequestering PIP2. Incubation 
of hiPS-derived cardiomyocytes with WT-Tat also leads to a decrease in IKr and acceleration 
of deactivation, consistent with a decrease in available PIP2. Finally, the cells electrical 
activity is affected through delayed repolarization and AP alternans. Altogether, these results 
indicate that Tat may affect cardiomyocytes repolarization through an interaction with PIP2, 
reducing the major repolarizing currents IKr and IKs. Those results are particularly significant 
as, despite the proven effect of PIP2 on the gating of many channels, the relevance of such a 
regulation in physiological or pathophysiological conditions is still questioned. It has been 
suggested that in cardiac cells, PIP2 levels are not affected enough by PLC-coupled receptors 
to alter IKr and IKs [38]. This work enlightens a pathophysiological condition where IKr is 
indeed reduced through a decrease in available PIP2. We also show that other PIP2-sentitive 
channels, such as the KATP channel [45] may also be affected. Since this channel is implicated 
in the ischemic preconditioning, this could explain at least partly the increase in acute 
myocardial infarction in HIV-patients adjusted for hypertension, diabetes, and dyslipidemia 
[46]. In human cardiomyocytes, we did not observe any effect of Tat incubation on the 
transient calcium current ICaL, despite its described PIP2 sensitivity [41]. This observation 
supports the hypothesis that channel activity is differentially modulated depending on its 
affinity for PIP2 [47]. 
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Tat incubation affected IKr in human cardiomyocytes, but not in COS-7 and HEK293 models. 
This highlights the usefulness of hiPS-derived cardiomyocytes as a more reliable model than 
heterologous systems. Most importantly, it validates the use of hiPS-CMs to study cardiac 
non-genetic diseases such as infectious diseases like AIDS. One could consider the absence of 
detectable IKs in non-stimulated condition as a limit of this model. But this characteristic 
makes this model closer to hardly available human cardiomyocytes [48, 49] as compared to 
guinea pig cardiomyocytes [50] in which IKs presents a much larger contribution to the 
repolarizing currents without any adrenergic stimulus. 
 
Bai and collaborators did observe an effect of Tat incubation on hERG current amplitude in a 
similar HEK293 model as we used [16]. However, these authors used a short isoform of Tat 
encoded by the first exon of the protein only (72 residues; Tat-72). The Tat protein used in 
our study is a 86 residues long (Tat-86), two-exon form of Tat that is present in viral isolates 
[34]. Although both Tat-72 and Tat-86 contain the transactivation domain, and are frequently 
used for in vitro studies, Tat-86 is more readily taken up than Tat-72 by various cell types 
[51]. In addition, the second exon endows Tat with additional activities and is critical for both 
in vitro and in vivo HIV replication [52]. Therefore, the use of Tat-86 appears to be more 
relevant to evaluate HIV impact on human cardiomyocyte electrical activity. 
 
In LQT patients, T-wave alternans mirroring ventricular AP alternans are associated with 
delayed repolarization and are a known risk factor for sudden death [53]. In hiPS-derived 
cardiomyocytes, Tat incubation resulted in a significant reduction in IKr current, associated 
with ventricular AP prolongation, as would be expected, and alternans occurrence. Up to now, 
such human AP alterations could be addressed with in silico studies only. For example, 
similar AP prolongation at low rate and APD alternans at elevated rate were observed when 
IKr alterations due to a human LQT-related hERG mutation were implemented in a 
mathematical model of the human ventricular action potential [54]. Similarly, mild reduction 
in repolarization reserve due to alteration of IKr parameters led to APD alternans using another 
in silico model [55]. These results are also in agreement with the observations in canine 
cardiomyocytes of AP alternans suppression by overexpression of hERG [56]. However, in 
silico or animal models are limited to investigate the potential multiple effects of actors such 
as Tat on their various mechanistic targets, in a situation far more complex than a single 
mutation. 
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In conclusion, this study strongly suggests that PIP2 is the link between HIV-Tat and the 
cardiac arrhythmias observed in HIV-positive individuals. In neurosecretory cells, it has been 
proposed that Tat perturbs the recruitment of several PIP2-dependent key players of the 
exocytotic machinery [32]. Combined with this previous investigation, our work suggests a 
general remodeling of PIP2-dependent processes by HIV via Tat. It would be interesting to 
test whether other processes, immune or not immune, are also affected by Tat through PIP2. 
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